Titan Biotech Limited has delivered impressive financial performance in Q3FY26, showcasing strong operational growth and profitability improvements. The company announced its unaudited financial results for the quarter and nine months ended December 31, 2025, at a Board meeting held on February 12, 2026.

Strong Revenue Growth Drives Performance

The company demonstrated robust top-line growth with revenue from operations reaching ₹5,650.57 lakhs in Q3FY26, representing a substantial 47.64% increase from ₹3,827.38 lakhs in Q3FY25. Sequential growth was also positive, with revenue rising 3.96% from ₹5,435.47 lakhs in Q2FY26.

Exceptional Profitability Improvement

Titan Biotech's profitability metrics showed remarkable improvement across all parameters. Net profit after tax more than doubled to ₹786.82 lakhs in Q3FY26 from ₹380.19 lakhs in the corresponding quarter last year, marking a 107.01% year-over-year increase. The profit before tax also witnessed strong growth of 106.89%, rising to ₹1,056.21 lakhs from ₹510.49 lakhs.

Basic earnings per share improved significantly to ₹9.52 from ₹4.60 in Q3FY25, reflecting the enhanced profitability per share. The company maintained healthy profit margins with effective cost management across various expense categories.

Nine-Month Performance Highlights

For the nine-month period ended December 31, 2025, Titan Biotech sustained its growth trajectory with total income of ₹16,066.06 lakhs compared to ₹12,381.33 lakhs in the corresponding period last year. Net profit for the nine months reached ₹2,089.15 lakhs, up from ₹1,450.50 lakhs in the previous year.

Consolidated Results Show Strong Performance

The consolidated financial results, which include associate companies Peptech Biosciences Limited and Titan Media Limited, demonstrated even stronger performance. Consolidated net profit after tax reached ₹852.86 lakhs in Q3FY26, with the company benefiting from ₹66.04 lakhs share in profit from associates.

Consolidated earnings per share stood at ₹10.32 for Q3FY26 compared to ₹5.31 in Q3FY25. For the nine-month period, consolidated net profit was ₹2,315.61 lakhs with earnings per share of ₹28.02.

Regulatory Compliance and Tax Optimization

The company has elected to exercise the option under section 115BAA of the Income Tax Act, 1961, optimizing its tax structure. The unaudited financial results have been prepared in accordance with Indian Accounting Standards (Ind AS) and reviewed by the statutory auditors A N S K & Associates.

The Board of Directors meeting commenced at 3:00 PM and concluded at 3:40 PM on February 12, 2026, with the results being made available on both BSE Limited's website and the company's official website at www.titanbiotechltd.com .

Titan Biotech Limited has announced the opening of a special window for transfer and dematerialization of physical securities, providing investors with a crucial opportunity to modernize their shareholdings and ensure better security of their investments.

SEBI Initiative for Investor Protection

Following SEBI Circular No. HO/38/13/11(2)2026-MIRSD-POD-I/3750/2026 dated January 30, 2026, the Securities and Exchange Board of India has opened another special window to facilitate ease of investing for investors and safeguard their rights in securities purchased prior to April 1, 2019. This regulatory initiative aims to encourage the conversion of physical securities to electronic form, enhancing investor protection and market efficiency.

Special Window Timeline and Coverage

The special window provides comprehensive coverage for various scenarios, including transfer requests that were submitted earlier but were rejected, returned, or not attended to due to deficiencies in documents, process, or other issues. This inclusive approach ensures that investors who faced difficulties in previous attempts can now complete their transactions successfully.

Process and Documentation Requirements

Investors who were unable to meet the earlier deadline of January 6, 2026, can now avail of this opportunity by furnishing the requisite documents to the company's designated Registrar and Transfer Agent. The process has been streamlined to ensure smooth execution of transfer and dematerialization requests.

Company Information and Accessibility

Titan Biotech Limited, incorporated under CIN: L74999RJ1992PLC013387, operates as an ISO 9001:2015 certified company with its corporate office located at 903-909, 9th Floor, Bigjos Tower, Netaji Subhash Place, Delhi-110034. The company maintains manufacturing units in Rajasthan and provides comprehensive information about this initiative on its website at www.titanbiotechltd.com .

The announcement was made by Charanjit Singh, Company Secretary and Compliance Officer (M. No.: A12726), emphasizing the company's commitment to facilitating smooth transitions for its shareholders. This initiative represents a significant step toward modernizing shareholding patterns and ensuring enhanced security for investor holdings in the digital age.